Fresenius Medical Care Forecast, price target & analysts
Fresenius Medical Care Target price 2025 - Analyst rating & recommendation
Fresenius Medical Care Classifications & Recommendation:
Fresenius Medical Care Price Target
| Target Price | €48.29 |
| Price | €49.94 |
| Deviation | 3.30% |
| Number of Estimates | 19 |
| 19 Analysts have issued a price target Fresenius Medical Care 2026 . The average Fresenius Medical Care target price is €48.29. This is 3.30% lower than the current stock price. The highest price target is €57.50 15.14% , the lowest is €37.00 25.91% . | |
| A rating was issued by 22 analysts: 8 Analysts recommend Fresenius Medical Care to buy, 9 to hold and 5 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Fresenius Medical Care stock has an average upside potential 2026 of 3.30% . Most analysts recommend the Fresenius Medical Care stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2029
17 Analysts have issued a sales forecast Fresenius Medical Care 2025 . The average Fresenius Medical Care sales estimate is €19.6b . This is 0.80% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €20.1b 2.86% , the lowest is €19.2b 1.63% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €19.3b | 0.60% |
|---|---|---|
| 2025 | €19.6b | 1.61% |
| 2026 | €20.3b | 3.47% |
| 2027 | €21.1b | 3.77% |
| 2028 | €22.1b | 4.55% |
| 2029 | €23.3b | 5.65% |
15 Analysts have issued an Fresenius Medical Care EBITDA forecast 2025. The average Fresenius Medical Care EBITDA estimate is €3.8b . This is 18.02% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €3.9b 22.35% , the lowest is €3.6b 13.67% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €3.2b | 0.64% |
|---|---|---|
| 2025 | €3.8b | 18.01% |
| 2026 | €3.9b | 3.73% |
| 2027 | €4.1b | 4.88% |
| 2028 | €4.2b | 2.62% |
| 2029 | €4.1b | 2.92% |
EBITDA Margin
| 2024 | 16.44% | 0.04% |
|---|---|---|
| 2025 | 19.10% | 16.16% |
| 2026 | 19.14% | 0.21% |
| 2027 | 19.35% | 1.10% |
| 2028 | 18.99% | 1.86% |
| 2029 | 17.45% | 8.11% |
13 Fresenius Medical Care Analysts have issued a net profit forecast 2025. The average Fresenius Medical Care net profit estimate is €953m . This is 54.01% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €1.0b 69.57% , the lowest is €883m 42.65% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | €537m | 7.65% |
|---|---|---|
| 2025 | €953m | 77.57% |
| 2026 | €1.2b | 22.04% |
| 2027 | €1.3b | 9.90% |
| 2028 | €1.6b | 25.64% |
| 2029 | €1.5b | 7.57% |
Net Margin
| 2024 | 2.78% | 8.29% |
|---|---|---|
| 2025 | 4.85% | 74.67% |
| 2026 | 5.72% | 17.94% |
| 2027 | 6.06% | 5.94% |
| 2028 | 7.28% | 20.13% |
| 2029 | 6.37% | 12.50% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
13 Analysts have issued a Fresenius Medical Care forecast for earnings per share. The average Fresenius Medical Care EPS is €3.25 . This is 54.03% higher than earnings per share in the financial year 2024. The highest EPS forecast is €3.58 69.67% , the lowest is €3.01 42.65% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €1.83 | 7.65% |
|---|---|---|
| 2025 | €3.25 | 77.60% |
| 2026 | €3.97 | 22.15% |
| 2027 | €4.36 | 9.82% |
| 2028 | €5.48 | 25.69% |
| 2029 | €5.06 | 7.66% |
P/E ratio
| Current | 23.70 | 2.69% |
|---|---|---|
| 2025 | 15.37 | 35.15% |
| 2026 | 12.59 | 18.09% |
| 2027 | 11.46 | 8.98% |
| 2028 | 9.12 | 20.42% |
| 2029 | 9.87 | 8.22% |
Based on analysts' sales estimates for 2025, the Fresenius Medical Care stock is valued at an EV/Sales of 1.30 and an P/S ratio of 0.75 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.31 | 10.08% |
|---|---|---|
| 2025 | 1.30 | 0.80% |
| 2026 | 1.26 | 3.36% |
| 2027 | 1.21 | 3.63% |
| 2028 | 1.16 | 4.35% |
| 2029 | 1.10 | 5.36% |
P/S ratio
| Current | 0.75 | 26.95% |
|---|---|---|
| 2025 | 0.75 | 0.80% |
| 2026 | 0.72 | 3.35% |
| 2027 | 0.69 | 3.64% |
| 2028 | 0.66 | 4.35% |
| 2029 | 0.63 | 5.34% |
Fresenius Medical Care...
Current Fresenius Medical Care Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Buy
➜
Buy
|
Unchanged | Mar 31 2025 |
| HSBC |
Hold
➜
Buy
|
Upgrade | Mar 23 2025 |
| JEFFERIES |
Underperform
➜
Underperform
|
Unchanged | Mar 20 2025 |
| METZLER EQUITIES |
Buy
➜
Buy
|
Unchanged | Feb 27 2025 |
| WARBURG RESEARCH GMBH |
Sell
➜
Hold
|
Upgrade | Feb 26 2025 |
| LANDESBANK BADEN-WUERTTEMBERG |
Hold
➜
Hold
|
Unchanged | Feb 25 2025 |
| ODDO BHF |
Buy
➜
Buy
|
Unchanged | Feb 24 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Mar 31 2025 |
|
Upgrade
HSBC:
Hold
➜
Buy
|
Mar 23 2025 |
|
Unchanged
JEFFERIES:
Underperform
➜
Underperform
|
Mar 20 2025 |
|
Unchanged
METZLER EQUITIES:
Buy
➜
Buy
|
Feb 27 2025 |
|
Upgrade
WARBURG RESEARCH GMBH:
Sell
➜
Hold
|
Feb 26 2025 |
|
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Hold
➜
Hold
|
Feb 25 2025 |
|
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Feb 24 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
